International Journal of Infectious Diseases
Volume 14, Issue 7 , Pages e548-e552 , July 2010

The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2

  • R.F. Chemaly

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 745 1116; fax: +1 713 745 6839.
    • ,
  • P.S. Sharma

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    • ,
  • S. Youssef

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    • ,
  • D. Gerber

      Affiliations

    • Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    • ,
  • P. Hwu

      Affiliations

    • Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    • ,
  • S.S. Hanmod

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    • ,
  • Y. Jiang

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    • ,
  • R.Y. Hachem

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    • ,
  • I.I. Raad

      Affiliations

    • Departments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA

Received 20 February 2009 ,Revised 17 July 2009 ,Accepted 10 August 2009.

References 

  1. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 2004;271:907–913
  2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116
  3. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6:S11–S14
  4. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55–S57
  6. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307–319
  7. Belldegrun A, Webb DE, Austin HA, Steinberg SM, Linehan WM, Rosenberg SA. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol. 1989;141:499–503
  8. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486–498
  9. Margolin K, Jaffe HS, Hawkins M. Toxicity of interleukin-2 and lymphokine-active killer cell therapy. Proc Am Soc Clin Oncol. 1987;6:251
  10. Guleria AS, Yang JC, Topalian SL, Weber DR, Parkinson DR, MacFarlane MP, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994;12:2714–2722
  11. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990;322:959–965
  12. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB. Nosocomial sepsis associated with interleukin-2. Ann Intern Med. 1990;112:102–107
  13. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenburg SA. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol. 1993;11:136–147
  14. Richards JM, Gilewski TA, Vogelzang NJ. Association of interleukin-2 therapy with staphylococcal bacteremia. Cancer. 1991;67:1570–1575
  15. Lim SH, Giles FJ, Smith MP, Goldstone AH. Bacterial infection in lymphoma patients treated with recombinant interleukin-2. Acta Haematol. 1991;85:135–138
  16. Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentruber DJ, Wei JP, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol. 1990;8:161–169
  17. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–1771
  18. O’Grady N, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2002;23:759–769
  19. Mermel LA, Farr BM, Sherertz RJ, Raad II, O’Grady N, Harris JS, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249–1272
  20. Chatzinikolaou I, Hanna H, Darouiche R, Samonis G, Tarrand J, Raad I. Prospective study of the value of quantitative culture of organisms from blood collected through central venous catheters in differentiating between contamination and bloodstream infection. J Clin Microbiol. 2006;44:1834–1835
  21. Raad II, Hachem RY, Abi-Said D, Rolston KVI, Whimbey E, Buzaid AC, et al. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer. 1998;82:403–411
  22. Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, et al. Induction of circulating tumor necrosis factor (TNF-alpha) as the mechanism for febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. 1988;8:426–436
  23. Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant tumor necrosis factor-alpha: regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest. 1988;82:759–765
  24. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother. 2008;61:26–38
  25. Raad I, Darouiche R, Dupuis J, Abisaid D, Gabrielli A, Hachem R, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Ann Intern Med. 1997;127:267–274
  26. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1–8
  27. Hanna HA, Raad II, Hackett B, Wallace SK, Price KJ, Coyle DE, et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest. 2003;124:1030–1038
  28. Chatzinikolaou I, Hanna H, Graviss L, Chaiban G, Perego C, Arbuckle R, et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol. 2003;24:961–963
  29. Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22:3163–3171
  30. Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall MJ, Metzler MH, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters. A randomized controlled trial. Ann Surg. 2005;242:193–200
  31. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;59:359–369
  32. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis. 1996;173:418–424
  33. Hanna H, Bahna P, Reitzel R, Dvorak T, Chaiban G, Hachem R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Chemother. 2006;50:3283–3288
  34. Aslam S, Darouiche RO. Prolonged bacterial exposure to minocycline/rifampicin-impregnated vascular catheters does not affect antimicrobial activity of catheters. J Antimicrob Chemother. 2007;60:148–151
  35. Munson EL, Heard SO, Doern GV. In vitro exposure of bacteria to antimicrobial impregnated-central venous catheters does not directly lead to the emergence of antimicrobial resistance. Chest. 2004;126:1628–1635
  36. Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control. 2003;31:1–8
  37. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters. Potential financial implications. Chest. 2003;124:275–284
  38. León C, Ruiz-Santana S, Rello J, Torre M, Valles J, Alvarez-Lerma F, et al. Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med. 2004;30:1891–1899
  39. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with a moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial – AIDS Clinical trials Group 328. Arch Intern Med. 2007;167:597–605

☆ Presented in part at the 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, USA, October 4–7, 2007.

PII: S1201-9712(09)00341-5

doi: 10.1016/j.ijid.2009.08.007

International Journal of Infectious Diseases
Volume 14, Issue 7 , Pages e548-e552 , July 2010

Article Tools

* Image Usage & Resolution